NCT02509195 - SSAT064: Pharmacokinetics of Abacavir/Lamivudine/Dolutegravir in HIV Patients of 60 Years and Over | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 4, 2015

Primary Completion Date

February 13, 2017

Study Completion Date

July 24, 2017

Conditions

HIV

Interventions

DRUG

Triumeq

Subjects will take the last dose of their current antiretroviral combination at its usual time on the day before the baseline visit (day 1) and will switch on day 1 to Abacavir/lamivudine/dolutegravir 600mg/300mg/50mg (Triumeq) fixed dose combination once daily between day 1 and day 180.

Trial Locations (1)

SW10 9NH

St Stephen's Centre, Chelsea & Westminster Hospital, London